CSI Market
Sign In | Register

Aptose Biosciences Inc (APTO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access APTO quarterly Cash Flow →
The data below summarizes Aptose Biosciences Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-25.47
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.48
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Operating Lease Expense-
Interest On Lease Liabilities0.06
Interest Accrued On Investments-
Increase Decrease In Accounts Payable Excluding Related Parties-2.23
Increase Decrease In Operating Lease Liability-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.00
Increase (Decrease) in Accrued Liabilities3.43
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.04
Other Working Capital2.96
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-21.99
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings18.65
Long-term debt - repayments0.10
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.83
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations9.25
Cost Of Offering-
Cost Of Offering-
Proceeds From Issuance Of Common Stock Under S1 Filing-
Shares Issuances To Hanmi-
Shares Issuances To Hanmi-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities19.38
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-21.99
Total Cash Flow-2.61
4 historic quarters locked

Sign in to unlock the full Aptose Biosciences Inc cash flow history.

Sign In Create Free Account

About Aptose Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-135012

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document